Guerreiro Castro, S;
Isenberg, DA;
(2017)
Belimumab in systemic lupus erythematosus (SLE): evidence-to-date and clinical usefulness.
Therapeutic Advances in Musculoskeletal Disease
, 9
(3)
pp. 75-85.
10.1177/1759720X17690474.
Preview |
Text
Isenberg_Belimumab.final.pdf - Accepted Version Download (499kB) | Preview |
Abstract
Systemic lupus erythematosus (SLE) is a complex autoimmune rheumatic disease with multiple presentations, whose management presents many challenges. Many disease modifying or immunosuppressive drugs have been used with limited success, especially in patients with more severe disease activity. Belimumab is the first drug to be approved specifically for the treatment of SLE in more than 50 years. By blocking the B-cell activating factor, it interferes in B-cell differentiation and survival. Here we consider the results of the clinical trials that led to its approval, as well as the post-hoc analyses, follow-up studies and the current trials.
Type: | Article |
---|---|
Title: | Belimumab in systemic lupus erythematosus (SLE): evidence-to-date and clinical usefulness |
Location: | England |
Open access status: | An open access version is available from UCL Discovery |
DOI: | 10.1177/1759720X17690474 |
Publisher version: | https://doi.org/10.1177/1759720X17690474 |
Language: | English |
Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
Keywords: | Belimumab, biologic therapy, immunosuppressive agents, systemic lupus erythematosus |
UCL classification: | UCL UCL > Provost and Vice Provost Offices UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Inflammation |
URI: | https://discovery.ucl.ac.uk/id/eprint/1551446 |
Archive Staff Only
![]() |
View Item |